Lotronex Risk Management Plan Should Not Be Changed Until More Safety Data Is Collected, Cmte. Says

Drug Safety & Risk Management Advisory Committee recommends that RMP should not be altered to increase access to Lotronex. The members suggest GlaxoSmithKline should focus on physician education.